 |
|
|
| |
The safety and pharmacokinetics of ABI-4334,
a novel next-generation HBV core inhibitor:
Interim results from a Phase 1 study in healthy volunteers
|
| |
| |
EASL 2023 june 21-24 vienna
Edward J. Gane1, Christian Schwabe2, Jieming Liu3, Luisa M. Stamm3, Kathryn M. Kitrinos3, Steven J. Knox3, Michele Anderson3, Grace Wang3, Katie Zomorodi3
1University of Auckland, Auckland, New Zealand; 2New Zealand Clinical Research, Auckland, New Zealand; 3Assembly Biosciences, Inc., South San Francisco, CA, USA
|
| |
|
|
|
|
|
